A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle

Feng, Zhen-Han; Li, Zhantao; Zhang, Shuang; Wang, Jingru; Li, Zhuoyue; Xu, Meiqi; Li, Hui; Zhang, Shuaiqiang; Wang, Guang-xue; Liao, Ai Ho; Zhang, Xuan

doi:10.1016/j.actbio.2021.09.052

Cited by 32 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-tumor immune response involves a cascade of cancer immune cycles. A mild PTT based on AuNRs-doxorubicin gel, combined with antigen-trapping liposomes and anti-PD-L1 drugs, can promote the positive transfer of the cancer immune cycle [ 118 ].…”

Section: Aunrs-ptt In Tumorsmentioning

confidence: 99%

Gold Nanorods-Based Photothermal Therapy: Interactions Between Biostructure, Nanomaterial, and Near-Infrared Irradiation

Zhou

Zhang

et al. 2022

Nanoscale Res Lett

View full text Add to dashboard Cite

Gold nanorods (AuNRs) are ideal inorganic nanophotothermal agents with unique characteristics, including local surface plasmon resonance effects, easy scale preparation and functional modification, and good biocompatibility. This review summarizes several recent advances in AuNRs-based photothermal therapy (PTT) research. Functionalized AuNRs photothermal agents have optimized biocompatibility and targeting properties. The multifunctional AuNRs nanoplatform composite structure meets the requirements for synergistic effects of PTT, photoacoustic imaging, and other therapeutic methods. Photothermal therapy with AuNRs (AuNRs-PTT) is widely used to treat tumors and inflammatory diseases; its tumor-targeting, tumor metastasis inhibition, and photothermal tumor ablation abilities have remarkable curative effects. An in-depth study of AuNRs in living systems and the interactions between biological structure, nanomaterial, and near-infrared irradiation could lay the foundation for further clinical research and the broad application of AuNRs in PTT.

show abstract

Section: Aunrs-ptt In Tumorsmentioning

confidence: 99%

Gold Nanorods-Based Photothermal Therapy: Interactions Between Biostructure, Nanomaterial, and Near-Infrared Irradiation

Zhou

Zhang

et al. 2022

Nanoscale Res Lett

View full text Add to dashboard Cite

show abstract

“…From this point of view, the investigation of ICD will provide new approaches for tumor treatment in EGFR-mutant NSCLC. Practically, a study has proven that combined antigen-capturing treatment and ICIs have a positive impact on the cancerimmunity cycle (75).…”

Section: Decreased Release Of Mhc-i and Mhc-ii Neoantigensmentioning

confidence: 99%

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are effective against advanced and even perioperative non-small-cell lung cancer (NSCLC) and result in durable clinical benefit, regardless of programmed death ligand-1 (PD-L1) expression status in cancer. Existing clinical evidence shows that the effect of immunotherapy in patients with EGFR-mutant NSCLC after the development of tyrosine kinase inhibitor (TKI) resistance is not satisfactory. However, compared with monotherapy, ICIs combined with chemotherapy can improve the efficacy. Encouragingly, compared with that of patients with sensitive mutations, the progression-free survival of patients with rare mutations who were treated with ICIs was increased. Adequately maximizing the efficacy of ICIs in EGFR-mutant NSCLC patients is worth exploring. In this review, we described preclinical and clinical studies of ICIs or combined therapy for EGFR-mutant NSCLC. We further focused on EGFR mutations and the cancer immune response, with particular attention given to the role of EGFR activation in the cancer-immunity cycle. The mechanisms for the natural resistance to ICIs were explored to identify corresponding countermeasures that made more EGFR-mutant NSCLC patients benefit from ICIs.

show abstract

“…39 This temperature-dependent drug release property makes thermosensitive liposomes useful carriers to combine PTT with anticancer drugs. 40,41 However, the delivery of free liposomes via intravenous injection also has the problems of immunological clearance and low accumulation at the targeted cancer cells. However, delivery through scaffold implantation is an attractive approach to achieve high local accumulation while avoiding immunological clearance.…”

Section: Introductionmentioning

confidence: 99%

Doxorubicin-encapsulated thermosensitive liposome-functionalized photothermal composite scaffolds for synergistic photothermal therapy and chemotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle

Cited by 32 publications

References 47 publications

Gold Nanorods-Based Photothermal Therapy: Interactions Between Biostructure, Nanomaterial, and Near-Infrared Irradiation

Gold Nanorods-Based Photothermal Therapy: Interactions Between Biostructure, Nanomaterial, and Near-Infrared Irradiation

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects

Doxorubicin-encapsulated thermosensitive liposome-functionalized photothermal composite scaffolds for synergistic photothermal therapy and chemotherapy

Contact Info

Product

Resources

About